Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz To Acquire Aspen’s Japanese Operations

Up to €400m Deal Strengthens Hospitals Portfolio

Executive Summary

Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.

You may also be interested in...



Biocon And Sandoz Join Hands On Japanese Humira Biosimilar

Biocon is looking to tap the global marketing clout of Sandoz by striking a deal to hand over distribution rights to its Humira (adalimumab) biosimilar in Japan.

Aspen Continues Chinese Voyage By Acquiring Sandoz’s Local Operations

Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.

Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership

Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel